Dipna Pharmachem Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Dipna Pharmachem Ltd is ₹ 8 as of 04 May 11:11 . The P/E Ratio of Dipna Pharmachem Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Dipna Pharmachem Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Dipna Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Dipna Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Dipna Pharmachem Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Dipna Pharmachem Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Dipna Pharmachem Ltd

Dipan Pharmachem Limited was incorporated on July 19, 2011.
Subsequently, the Company name was changed to 'Dipna Pharmachem Private Limited' on March 29, 2012.
Later on, it was converted from Private Limited to Public Limited and the name of Company was changed to 'Dipna Pharmachem Limited' vide fresh Certificate of Incorporation issued by Registrar of Companies, Ahmedabad dated May 25, 2022. Dipna Pharmachem Limited is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011.
Presently, its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Dipna Pharmachem Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Dipna Pharmachem Ltd or Sanofi India Ltd?

Market cap of Dipna Pharmachem Ltd is 20 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Dipna Pharmachem Ltd and Sanofi India Ltd?

The stock performance of Dipna Pharmachem Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dipna Pharmachem Ltd and Sanofi India Ltd?

As of May 4, 2026, the Dipna Pharmachem Ltd stock price is INR ₹7.94. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Dipna Pharmachem Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Dipna Pharmachem Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.